[1]
|
Siegel, R.L., Miller, K.D., Fuchs, H.E., et al. (2021) Cancer Statistics, 2021. CA: A Cancer Journal for Clinicians, 71, 7-33. https://doi.org/10.3322/caac.21654
|
[2]
|
Chen, L., Hou, Y., Xia, Y., et al. (2020) Radiotherapy Dose and In-duction Chemotherapy Cycles Are Associated with Prognosis and Toxicity Risk: A Retrospective Study of 227 Patients with Unresectable Stage III Non-Small-Cell Lung Cancer. Technology in Cancer Research & Treatment, 19, 1-8. https://doi.org/10.1177/1533033820951802
|
[3]
|
Zhou, C., Wu, Y., Chen, G., et al. (2015) BEYOND: A Ran-domized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients with Advanced or Recurrent Nonsquamous Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 33, 2197-2204.
https://doi.org/10.1200/JCO.2014.59.4424
|
[4]
|
Gridelli, C., Maione, P. and Rossi, A. (2013) The PARAMOUNT Trial: A Phase III Randomized Study of Maintenance Pemetrexed versus Placebo Immediately Following Induction First-Line Treatment with Pemetrexed plus Cisplatin for Advanced Nonsquamous Non-Small Cell Lung Cancer. Reviews on Recent Clinical Trials, 8, 23-28.
https://doi.org/10.2174/15748871112079990040
|
[5]
|
Lu, J., Chu, T., Liu, H., et al. (2022) Equivalent Efficacy Assessment of QL1101 and Bevacizumab in Nonsquamous Non-Small Cell Lung Cancer Patients: A Two-Year Fol-low-Up Data Update. Chinese Journal of Cancer Research, 34, 28-39. https://doi.org/10.21147/j.issn.1000-9604.2022.01.03
|
[6]
|
Christ, S.M., Pohl, K., Muehlematter, U.J., et al. (2022) Imaging-Based Prevalence of Oligometastatic Disease: A Single-Center Cross-Sectional Study. International Journal of Radiation Oncology Biology Physics, 114, 596-602.
https://doi.org/10.1016/j.ijrobp.2022.06.100
|
[7]
|
Torok, J.A., Gu, L., Tandberg, D.J., et al. (2017) Patterns of Distant Metastases after Surgical Management of Non- Small-Cell Lung Cancer. Clinical Lung Cancer, 18, e57-e70. https://doi.org/10.1016/j.cllc.2016.06.011
|
[8]
|
Rusthoven, K.E., Hammerman, S.F., Kavanagh, B.D., et al. (2009) Is There a Role for Consolidative Stereotactic Body Radiation Therapy Following First-Line Systemic Therapy for Meta-static Lung cancer? A Patterns-of-Failure Analysis. Acta Oncologica, 48, 578-583. https://doi.org/10.1080/02841860802662722
|
[9]
|
Tran, P.T., Sutera, P., Phillips, R.M., et al. (2022) From Idea to Clinical Practice: A Brief History of Oligometastatic Disease. International Journal of Radiation Oncology, Biology, Physics, 114, 576-580.
https://doi.org/10.1016/j.ijrobp.2022.04.004
|
[10]
|
Milano, M.T., Biswas, T., Simone, C.N., et al. (2021) Oligome-tastases: History of a Hypothesis. Annals of Palliative Medicine, 10, 5923-5930. https://doi.org/10.21037/apm.2020.03.31
|
[11]
|
Gutiontov, S.I., Pitroda, S.P., Tran, P.T., et al. (2021) (Oli-go)metastasis as a Spectrum of Disease. Cancer Research, 81, 2577-2583. https://doi.org/10.1158/0008-5472.CAN-20-3337
|
[12]
|
Guckenberger, M., Lievens, Y., Bouma, A.B., et al. (2020) Characterisation and Classification of Oligometastatic Disease: A European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer Consensus Recommendation. The Lancet Oncology, 21, e18-e28.
https://doi.org/10.1016/S1470-2045(19)30718-1
|
[13]
|
Lievens, Y., Guckenberger, M., Gomez, D., et al. (2020) Defining Oligometastatic Disease from a Radiation Oncology Perspective: An ESTRO-ASTRO Consensus Document. Radiotherapy and Oncology, 148, 157-166.
https://doi.org/10.1016/j.radonc.2020.04.003
|
[14]
|
Iyengar, P., All, S., Berry, M.F., et al. (2023) Treatment of Oli-gometastatic Non-Small Cell Lung Cancer: An ASTRO/ ESTRO Clinical Practice Guideline. Practical Radiation Oncol-ogy. https://doi.org/10.1016/j.prro.2023.04.004
|
[15]
|
Kroeze, S.G.C., Pavic, M., Stellamans, K., et al. (2023) Me-tastases-Directed Stereotactic Body Radiotherapy in Combination with Targeted Therapy or Immunotherapy: Systematic Review and Consensus Recommendations by the EORTC-ESTRO OligoCare Consortium. The Lancet Oncology, 24, e121-e132.
https://doi.org/10.1016/S1470-2045(22)00752-5
|
[16]
|
Kwint, M., Walraven, I., Burgers, S., et al. (2017) Outcome of Radical Local Treatment of Non-Small Cell Lung Cancer Patients with Synchronous Oligometastases. Lung Cancer (Amsterdam, Netherlands), 112, 134-139.
https://doi.org/10.1016/j.lungcan.2017.08.006
|
[17]
|
Xu, Q., Zhou, F., Liu, H., et al. (2018) Consolidative Local Ablative Therapy Improves the Survival of Patients with Synchronous Oligometastatic NSCLC Harboring EGFR Acti-vating Mutation Treated with First-Line EGFR-TKIs. Journal of Thoracic Oncology, 13, 1383-1392. https://doi.org/10.1016/j.jtho.2018.05.019
|
[18]
|
Mitchell, K.G., Farooqi, A., Ludmir, E.B., et al. (2021) Pulmonary Resection Is Associated with Long-Term Survival and Should Remain a Therapeutic Option in Oligometastatic Lung Cancer. The Journal of Thoracic and Cardiovascular Surgery, 161, 1497-1504. https://doi.org/10.1016/j.jtcvs.2020.02.134
|
[19]
|
Ni, Y., Peng, J., Yang, X., et al. (2021) Multicentre Study of Mi-crowave Ablation for Pulmonary Oligorecurrence after Radical Resection of Non-Small-Cell Lung Cancer. British Jour-nal of Cancer, 125, 672-678.
https://doi.org/10.1038/s41416-021-01404-y
|
[20]
|
Kodama, H., Yamakado, K., Takaki, H., et al. (2012) Lung Ra-diofrequency Ablation for the Treatment of Unresectable Recurrent Non-Small-Cell Lung Cancer after Surgical Interven-tion. CardioVascular and Interventional Radiology, 35, 563-569. https://doi.org/10.1007/s00270-011-0220-0
|
[21]
|
Wei, Z., Ye, X., Yang, X., et al. (2019) Efficacy and Safety of Microwave Ablation in the Treatment of Patients with Oligometastatic Non-Small-Cell Lung Cancer: A Retrospective Study. International Journal of Hyperthermia, 36, 826-833. https://doi.org/10.1080/02656736.2019.1642522
|
[22]
|
Ni, Y., Bi, J., Ye, X., et al. (2016) Local Microwave Abla-tion with Continued EGFR Tyrosine Kinase Inhibitor as a Treatment Strategy in Advanced Non-Small Cell Lung Cancers That Developed Extra-Central Nervous System Oligoprogressive Disease during EGFR Tyrosine Kinase Inhibitor Treatment: A Pilot Study. Medicine (Baltimore), 95, e3998. https://doi.org/10.1097/MD.0000000000003998
|
[23]
|
刘宝东, 刘磊, 胡牧, 等. 肺癌切除术后肺内孤立性转移复发灶的射频消融治疗[J]. 中国肺癌杂志, 2014, 17(6): 460-464.
|
[24]
|
Ni, Y., Liu, B., Ye, X., et al. (2019) Local Thermal Ablation with Continuous EGFR Tyrosine Kinase In-hibitors for EGFR-Mutant Non-Small Cell Lung Cancers that Developed Extra-Central Nervous System (CNS) Oli-goprogressive Disease. Cardiovascular and Interventional Radiology, 42, 693-699. https://doi.org/10.1007/s00270-018-02153-x
|
[25]
|
Li, X., Zhao, M., Wang, J., et al. (2013) Percutaneous CT-Guided Radiofrequency Ablation as Supplemental Therapy after Systemic Chemotherapy for Selected Advanced Non-Small Cell Lung Cancers. American Journal of Roentgenology (1976), 201, 1362. https://doi.org/10.2214/AJR.12.10511
|
[26]
|
Schoellnast, H., Deodhar, A., Hsu, M., et al. (2012) Recurrent Non-Small Cell Lung Cancer: Evaluation of CT-Guided Radiofrequency Ablation as Salvage Therapy. Acta Radiologica (1987), 53, 893-899.
https://doi.org/10.1258/ar.2012.110333
|
[27]
|
刘宝东, 李元博, 胡牧, 等. 射频消融在EGFR-TKIs治疗非小细胞肺癌后局部进展的初步临床应用[J]. 中国肺癌杂志, 2016, 19(12): 859-863.
|
[28]
|
Iyengar, P., Wardak, Z., Gerber, D.E., et al. (2018) Consolidative Radiotherapy for Limited Metastatic Non-Small-Cell Lung Cancer: A Phase 2 Random-ized Clinical Trial. JAMA Oncology, 4, e173501.
https://doi.org/10.1001/jamaoncol.2017.3501
|
[29]
|
Gomez, D.R., Blumenschein, G.R., Lee, J.J., et al. (2016) Local Consolidative Therapy versus Maintenance Therapy or Observation for Patients with Oligometastatic Non-Small-Cell Lung Cancer without Progression after First-Line Systemic Therapy: A Multicentre, Randomised, Controlled, Phase 2 Study. The Lancet Oncology, 17, 1672-1682.
https://doi.org/10.1016/S1470-2045(16)30532-0
|
[30]
|
Gomez, D.R., Tang, C., Zhang, J., et al. (2019) Local Con-solidative Therapy vs. Maintenance Therapy or Observation for Patients with Oligometastatic Non-Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study. Journal of Clinical Oncology, 37, 1558-1565. https://doi.org/10.1200/JCO.19.00201
|
[31]
|
Wang, X., Bai, Y., Verma, V., et al. (2023) Randomized Trial of First-Line Tyrosine Kinase Inhibitor with or without Radiotherapy for Synchronous Oligometastatic EGFR-Mutated Non-Small Cell Lung Cancer. JNCI: Journal of the National Cancer Institute, 115, 742-748. https://doi.org/10.1093/jnci/djac015
|
[32]
|
Theelen, W.S.M.E., Chen, D., Verma, V., et al. (2021) Pembrolizumab with or without Radiotherapy for Metastatic Non-Small-Cell Lung Cancer: A Pooled Analysis of Two Randomised Trials. The Lancet Respiratory Medicine, 9, 467-475. https://doi.org/10.1016/S2213-2600(20)30391-X
|
[33]
|
Theelen, W., Peulen, H., Lalezari, F., et al. (2019) Effect of Pembrolizumab after Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients with Advanced Non-Small Cell Lung Cancer: Results of the PEMBRO-RT Phase 2 Randomized Clinical Trial. JAMA Oncology, 5, 1276-1282.
https://doi.org/10.1001/jamaoncol.2019.1478
|
[34]
|
Petrelli, F., Ghidini, A., Cabiddu, M., et al. (2018) Addition of Radiotherapy to the Primary Tumour in Oligometastatic NSCLC: A Systematic Review and Meta-Analysis. Lung Cancer (Amsterdam, Netherlands), 126, 194-200.
https://doi.org/10.1016/j.lungcan.2018.11.017
|
[35]
|
Bauml, J.M., Mick, R., Ciunci, C., et al. (2019) Pembrolizumab after Completion of Locally Ablative Therapy for Oligometastatic Non-Small Cell Lung Cancer: A Phase 2 Trial. JAMA Oncology, 5, 1283-1290.
https://doi.org/10.1001/jamaoncol.2019.1449
|
[36]
|
Katipally, R.R., Pitroda, S.P., Juloori, A., et al. (2022) The Oli-gometastatic Spectrum in the Era of Improved Detection and Modern Systemic Therapy. Nature Reviews. Clinical On-cology, 19, 585-599.
https://doi.org/10.1038/s41571-022-00655-9
|
[37]
|
Garde-Noguera, J., Martin-Martin, M., Obeso, A., et al. (2022) Current Treatment Landscape for Oligometastatic Non-Small Cell Lung Cancer. World Journal of Clinical Oncology, 13, 485-495.
https://doi.org/10.5306/wjco.v13.i6.485
|
[38]
|
Jasper, K., Stiles, B., McDonald, F., et al. (2022) Practical Manage-ment of Oligometastatic Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 40, 635-641. https://doi.org/10.1200/JCO.21.01719
|